I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Associate Manager - Systems Engineering & Algorithms

Full-TimeUpdated on 10/23/2026
No salary listed
Senior, Expert
Master's, PhD
Haifa, Israel
In Person
Engineering ManagementEngineering Leadership

About the job

Requirements
  • An advanced degree (M.Sc. or Ph.D.) in Engineering, Physics, Applied Mathematics, Computer Science, or a related field is preferred.
  • Experience developing signal-processing, control, imaging, data-analysis, or optimization algorithms.
  • Experience with modeling and simulation environments.
  • Strong statistical and analytical skills.
  • Experience translating clinical or user needs into quantitative performance requirements.
  • Strong understanding of Design Controls, IEC 62304, IEC 60601, ISO 14971, and applicable medical device regulations.
  • Experience working in Agile and hybrid product development environments.
  • At least 8 years of experience as a Systems, Integration, Hardware, Software, Mechanical, or Biomedical Engineer.
  • At least 3 years of Systems Engineering experience in a medical device company.
  • Proven ability to develop timely and effective solutions for challenging design problems.
  • Experience with requirements management and traceability tools and methodologies.
  • Familiarity with Quality Management Systems, design controls, and risk management in regulated environments and medical devices.
Responsibilities
  • Lead the definition, development, and maintenance of system and hardware requirements.
  • Establish and drive algorithms development methodologies, processes, and best practices.
  • Establish and maintain hardware requirements, including reviews, approvals, change management, and traceability.
  • Ensure hardware requirements and algorithm definitions are complete, testable, traceable, and aligned with product and regulatory needs.
  • Own hardware and algorithm requirements traceability throughout the product development lifecycle.
  • Support architecture, design, and risk management activities through requirements-based engineering.
  • Own algorithm requirements, performance specifications, acceptance criteria, and traceability throughout the product lifecycle.
  • Lead development of proprietary algorithms supporting product functionality and differentiation.
  • Establish methodologies for algorithm verification, validation, and performance characterization.
  • Oversee Proof-of-Design activities demonstrating technical feasibility and performance.
  • Support intellectual property generation and innovation initiatives.
  • Lead development of system models and simulations supporting design decisions and proof-of-concept evaluations.
  • Establish methodologies for predictive analysis and system performance assessment.
  • Leverage simulation results to support requirements development, risk analyses, and design optimization.
  • Support architecture trade-off analyses through data-driven modeling approaches.
  • Incorporate best practices and artificial intelligence as appropriate.
  • Define system integration strategies for hardware and software subsystems.
  • Lead integration planning, execution, and issue resolution activities.
  • Ensure subsystem interfaces are clearly defined and verified.
  • Support early identification and mitigation of integration risks.
  • Drive resolution of cross-functional integration issues and interface-related risks.
  • Lead, develop, and mentor a team of Systems Engineers.
  • Build organizational capability through coaching, mentoring, performance management, and career development of team members.
  • Serve as Agile Product Owner, managing team priorities, backlog, and sprint objectives.
  • Collaborate closely with Research and Development, Quality, Regulatory Affairs, Clinical, and Program Management teams.
  • Ensure alignment between requirements, design outputs, verification activities, and project goals.
  • Drive a culture of technical excellence, accountability, innovation, and continuous improvement.
  • Communicate business-related issues and opportunities with management.
  • Follow all applicable procedures and guidelines.
  • Ensure that direct reports follow all applicable procedures and guidelines.
  • Perform other duties assigned as needed by management.
Desired Qualifications
  • Previous leadership, project leadership, or people management experience, including military experience.
  • Development in Agile environments.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-Term Disability
  • Long-Term Disability
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Oct 22nd, 2026
Integra LifeSciences shares fall 11% despite $411.2M Q3 revenue and return to profit

Integra LifeSciences shares fell about 11% in the first full session after its third-quarter 2026 results, as investors focused on refinancing worries and a high price-to-earnings ratio. Revenue rose to $411.2 million from $402.1 million a year earlier. The company posted a net profit of $14.9 million, against a $5.4 million loss, or basic earnings per share of $0.19. Operating cash flow reached $96 million, and net leverage fell to 3.8x. Net debt remains about $1.6 billion. Integra plans to refinance through new $450 million 9.5% notes, at an estimated 100 to 200 basis points higher rate. It also forecasts higher interest costs in 2027 and a softer fourth-quarter organic outlook.

Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.